Extended Data Fig. 9: Autosomal mHAgs and GvHD.
a, Normal distribution of the autosomal mHAg load in the DFCI-MRD cohort. b, Cumulative incidence of NIH moderate/severe chronic GvHD stratifying patients based on the overall autosomal mHAg load below (orange) or above (yellow) the median: no differences in 5-year cumulative incidences are observed: CIs are 42% (95% confidence interval: 33–52%) and 39% (95% confidence interval: 30–49%) for < median and > median, respectively, 2-sided p = 0.8 (Gray’s test). c, Distribution of patients experiencing grade II–IV skin (left) and GI (right) acute GvHD across deciles of skin and GI mHAgs, respectively. d, Distribution of patients experiencing NIH moderate/severe organ-specific chronic GvHD across deciles of mHAgs expressed in the indicated GvHD target organs: from left to right—skin, GI, liver, eye and oral. e, Heatmap depicting the co-occurrence of the 7 SNPs associated with liver acute GvHD in: from left to right, patients with liver acute GvHD, patients experiencing acute GvHD without liver involvement and patients with chronic liver GvHD. f, Number of co-occurring driver liver mHAgs in the 3 patient groups outlined in e and defined with the same color code. Boxplots show min to max and median values (Kruskall–Wallis test with Dunn’s multiple comparison test). g, Promoter analysis of the genes harboring the SNPs associated with liver acute GvHD: 4 of 7 genes have interferon-responsive elements in their promoter region. Transcription factor binding site locations within 1500 base pairs (bp) upstream of the transcription start site (position 0) and the 5′ UTR are indicated.
